[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Montes
María Luisa
ML
Fraile
José María
JM
González
Juan Julián
JJ
Arribas
José Ramón
JR
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000928:Antidepressive Agents; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000139:chemically induced* / Q000188:drug therapy; D002819:Chorea / Q000139:chemically induced*; D015283:Citalopram / Q000627:therapeutic use; D003866:Depressive Disorder / Q000139:chemically induced* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy / Q000209:etiology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019338:Polypharmacy; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D012678:Sensation Disorders / Q000139:chemically induced; D013967:Thyroiditis, Autoimmune / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D013974:Thyroxine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000928:Antidepressive Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015283:Citalopram; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; D013974:Thyroxine